Press release
Investigation announced for Investors in shares of SCYNEXIS, Inc. (NASDAQ: SCYX) over possible Violations of Securities Laws
An investigation for investors in SCYNEXIS, Inc. (NASDAQ: SCYX) shares over potential securities laws violations by SCYNEXIS, Inc.
Investors who purchased shares of SCYNEXIS, Inc. (NASDAQ: SCYX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of SCYNEXIS, Inc. (NASDAQ: SCYX) concerning whether a series of statements by SCYNEXIS, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Jersey City, NJ based SCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. SCYNEXIS, Inc. reported that its annual Total Revenue declined from $13.16 million in 2021 to $5.09 million in 202, and that its Net Loss increased from $32.86 million in 2021 to $62.8 million in 2022.
Shares of SCYNEXIS, Inc. (NASDAQ: SCYX) declined from $3.87 per share on September 05, 2023, to as low as $1.625 per share on October 24, 2023.
Those who purchased shares of SCYNEXIS, Inc. (NASDAQ: SCYX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of SCYNEXIS, Inc. (NASDAQ: SCYX) over possible Violations of Securities Laws here
News-ID: 3263619 • Views: …
More Releases from Shareholders Foundation
Biohaven Ltd. (NYSE: BHVN) Investor Alert: Deadline in Lawsuit on September 12, …
A deadline is coming up on September 12, 2025in the lawsuit filed for certain investors of Biohaven Ltd. (NYSE: BHVN) over alleged securities laws violations by Biohaven Ltd.
Investors who purchased shares of Biohaven Ltd. (NYSE: BHVN) have certain options and there are strict and short deadlines running. Deadline: September 12, 2025. NYSE: BHVN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the…
Investigation announced for Long-Term Investors in shares of West Pharmaceutical …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of West Pharmaceutical Services, Inc..
Investors who are current long term investors in West Pharmaceutical Services, Inc. (NYSE: WST) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in (NYSE: WST stocks follows a lawsuit filed…
Investigation announced for Long-Term Investors in Open Lending Corporation (NAS …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Open Lending Corporation.
Investors who are current long term investors in Open Lending Corporation (NASDAQ: LPRO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: LPRO stocks follows a lawsuit filed against Open…
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings …
An investigation on behalf of current long-term investors in shares of BigBear.ai Holdings, Inc. (NYSE: BBAI) concerning potential breaches of fiduciary duties by certain directors and officers of BigBear.ai Holdings, Inc. was announced.
Investors who are current long term investors in BigBear.ai Holdings, Inc. (NYSE: BBAI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm…
More Releases for SCYNEXIS
Blastomycosis Treatment Market Overall Study Report 2025-2032 | Janssen, Scynexi …
The blastomycosis treatment market is estimated to be valued at USD 216.3 Mn in 2025 and is expected to reach USD 349.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 7.1% from 2025 to 2032.
The release of the report "Blastomycosis Treatment Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2032". This includes examining past deployments, current market conditions, and expected future deployments. This…
Systemic Inflammatory Response Syndrome Market to Rise by 2032 | Cidera Therapeu …
DelveInsight's "Systemic Inflammatory Response Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Systemic Inflammatory Response Syndrome, historical and forecasted epidemiology as well as the Systemic Inflammatory Response Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Systemic Inflammatory Response Syndrome market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and…
Investigation announced for Long-Term Investors in shares of SCYNEXIS, Inc. (NAS …
An investigation was announced for long-term investors in shares of SCYNEXIS, Inc. (NASDAQ: SCYX) concerning potential breaches of fiduciary duties by certain directors of SCYNEXIS, Inc.
Investors who are current long term investors in SCYNEXIS, Inc. (NASDAQ: SCYX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: SCYX stocks…
Lawsuit filed for Investors who lost money with shares of SCYNEXIS, Inc. (NASDAQ …
An investor, who purchased shares of SCYNEXIS, Inc. (NASDAQ: SCYX), filed a lawsuit over alleged violations of Federal Securities Laws by SCYNEXIS, Inc.
Investors who purchased shares of SCYNEXIS, Inc. (NASDAQ: SCYX) have certain options and for certain investors are short and strict deadlines running. Deadline: January 08, 2024. NASDAQ: SCYX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Jersey City, NJ based SCYNEXIS, Inc., a…
Systemic Inflammatory Response Syndrome Market to Witness Growth by 2032 | Compa …
DelveInsight's "Systemic Inflammatory Response Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Systemic Inflammatory Response Syndrome, historical and forecasted epidemiology as well as the Systemic Inflammatory Response Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Systemic Inflammatory Response Syndrome market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and…
Evotec & Scynexis to lead the workshops for Superbugs & Superdrugs 2020
SMi Reports: Interactive workshop overview for SMi's 22nd Annual Superbugs & Superdrugs Conference, London in March 2020
SMi’s highly anticipated 22nd Annual Superbugs & Superdrugs Conference will commence on the 30th and 31st March 2020 and in London, UK.
For this year’s conference, industry leaders and key profiles from leading pharmaceutical organisations will be brought together to discuss the strategies in place that reduce AMR, evaluate the role pharmaceutical companies and funding…
